OSE Immunotherapeutics (BATS-CHIXE:OSEP) - Cotización, noticias y análisis

Resumen de acción OSEP

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.

Acerca de la empresa

OSEP fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Recompensas

Cotiza un 94.2% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 33.77%

Análisis de riesgos

Acciones altamente ilíquidas

No tiene una capitalización de mercado significativa (€70M)

Competidores de OSE Immunotherapeutics SA

Tissue Regenix Group

AIM:TRX

UK£43.0m

Arecor Therapeutics

AIM:AREC

UK£42.1m

Oxford Biomedica

LSE:OXB

UK£287.0m

Bioventix

AIM:BVXP

UK£225.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for OSE Immunotherapeutics
Historical stock prices
Current Share Price	€5.52
52 Week High	€7.10
52 Week Low	€5.30
Beta	1.01
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-17.92%
3 Year Change	-9.51%
5 Year Change	n/a
Change since IPO	34.14%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	OSEP	GB Biotechs	Mercado GB
7D	0%	3.4%	1.1%
1Y	-17.9%	-25.7%	1.9%

Rentabilidad vs. Industria: OSEP superó al sector UK Biotechs , que obtuvo un rendimiento del -30.5% el año pasado.

Rentabilidad vs. Mercado: OSEP obtuvo unos resultados inferiores a los del mercado UK, que fue del -1.8% el año pasado.

Volatilidad de los precios

Is OSEP's price volatile compared to industry and market?
OSEP volatility
OSEP Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.5%
10% least volatile stocks in GB Market	2.7%

Precio estable de las acciones: OSEP no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de OSEP en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2012	60	Nicolas Poirier	www.ose-immuno.com

Resumen de fundamentos de OSE Immunotherapeutics SA

¿Cómo se comparan los beneficios e ingresos de OSE Immunotherapeutics con su capitalización de mercado?
Estadísticas fundamentales de OSEP
Capitalización bursátil	€69.51m
Beneficios(TTM)	-€17.76m
Ingresos (TTM)	€18.30m

3.8x

Ratio precio-ventas (PS)

-3.9x

Ratio precio-beneficio (PE)

¿Está OSEP sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de OSEP
Ingresos	€18.30m
Coste de los ingresos	€0
Beneficio bruto	€18.30m
Otros gastos	€36.06m
Beneficios	-€17.76m

Últimos beneficios comunicados

Dec 31, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.96
Margen bruto	100.00%
Margen de beneficio neto	-97.04%
Ratio deuda/patrimonio	123.5%

¿Cómo se ha desempeñado OSEP a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción OSEP

Recompensas

Análisis de riesgos

Competidores de OSE Immunotherapeutics SA

AIM:TRX

UK£43.0m

AIM:AREC

UK£42.1m

LSE:OXB

UK£287.0m

AIM:BVXP

UK£225.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors

OSE Immunotherapeutics SA and Nantes University Hospital Presents Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody

OSE Immunotherapeutics SA Announces Publication in Frontiers in Immunology on Ose-230, Its Novel Agonist Therapy in Chronic Inflammation

OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation

OSE Immunotherapeutics SA Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist

Recent updates

OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors

OSE Immunotherapeutics SA and Nantes University Hospital Presents Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody

OSE Immunotherapeutics SA Announces Publication in Frontiers in Immunology on Ose-230, Its Novel Agonist Therapy in Chronic Inflammation

OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation

OSE Immunotherapeutics SA Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist

OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director

OSE Immunotherapeutics SA Presents Clinical Abstracts on Tedopi at the ASCO 2023 Annual Meeting

OSE Immunotherapeutics SA, Annual General Meeting, Jun 22, 2023

OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announces Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi in Advanced Pancreatic Cancer

OSE Immunotherapeutics SA Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas

OSE Immunotherapeutics SA Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting

Ose Immunotherapeutics Announces Publication of Peer-Reviewed Data on Clec-1

Servier and OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome

OSE Immunotherapeutics SA Updates on Tedopi®, Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Appoints Nicolas Poirier as Chief Executive Officer

First half 2022 earnings released: €0.11 loss per share (vs €0.64 loss in 1H 2021)

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

OSE Immunotherapeutics SA Appoints Alexis Vandier as Chief Executive Officer

OSE Immunotherapeutics SA, Annual General Meeting, Jun 23, 2022

OSE Immunotherapeutics SA Appoints its International Scientific Advisory Board

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPa Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology

OSE Immunotherapeutics SA Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy

OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy

No longer forecast to breakeven

OSE Immunotherapeutics SA to Report Fiscal Year 2021 Results on Mar 30, 2022

Boehringer Ingelheim and OSE Immunotherapeutics to Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPa Inhibitor BI 765063 in Advanced Solid Tumors

OSE Immunotherapeutics SA Appoints Alexandre Lebeaut as Independent Member of the Board of Directors

OSE Immunotherapeutics SA Announces Acceptance of the US Investigational New Drug Application Obtained by Veloxis Pharmaceuticals, Inc., Its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de OSE Immunotherapeutics SA

3.8x

-3.9x

Beneficios e Ingresos